Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| 31.25 | |
| 30.6 | |
| - | |
| 32.1 | |
| 29.92 | |
| 12.57-42.5 | |
| 1 189 M | |
| 38 042 K | |
| 83 374 K | |
| -0.88 | |
| 1.067 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts. To skip our analysis of the recent market activity, you can go directly to see the Aggressive Stock Po...
Tarsus Pharmaceuticals, Inc. TARS shares soared 8.5% in the last trading session to close at $27.98. The move was backed by solid volume with far more shares changing hands than in a normal session. T...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
